In Brief:
In this multi-center, randomized, placebo-controlled, double-blind 12-week study in 94 healthy postmenopausal women, HMR 3339 induced a dose-dependent reduction in both asymmetric dimethylarginine, an emerging coronary heart disease risk marker that inhibits nitric oxide synthase, and its stereo-isomer symmetric dimethylarginine. Raloxifene had no effects on these two markers.